Montelukast Lek-Am

Montelukast, the active ingredient in Montelukast Lek-Am, is a leukotriene receptor antagonist presented as a tablet for oral use. It is used to manage asthma and allergic rhinitis in both adult and pediatric patients requiring maintenance therapy. It also helps reduce the frequency of asthma attacks and improves overall respiratory function.

GNH USA supplies Montelukast Lek-Am as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution to meet the needs of healthcare providers.

Montelukast is indicated for conditions involving leukotriene‑mediated inflammation, primarily within the respiratory tract.

- Asthma: maintenance therapy to control symptoms and reduce exacerbations. - Allergic rhinitis: relief of nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevention of airway narrowing during physical activity.

Montelukast may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache - Abdominal pain - Cough - Sore throat - Nausea - Diarrhea

Serious or Rare Side Effects: - Allergic reactions (rash, angioedema) - Mood changes (depression, suicidal thoughts) - Liver enzyme elevation - Severe skin reactions (Stevens‑Johnson syndrome) - Eosinophilic granulomatosis with polyangiitis - Anaphylaxis

When prescribing Montelukast, clinicians should consider several safety measures.

- Assess liver function: monitor hepatic enzymes in patients with pre‑existing liver disease. - Avoid use in patients with known hypersensitivity to montelukast or any tablet excipients. - Caution in patients with a history of psychiatric disorders: monitor for mood changes. - Consider dose adjustment in severe renal impairment: follow prescriber guidance. - Pregnancy and lactation: risk unknown, use only if clearly needed. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Montelukast can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Phenobarbital: may reduce montelukast plasma levels. - Rifampin: induces metabolism, decreasing efficacy. - Ketoconazole: may increase montelukast exposure.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of anticoagulant effect. - Beta‑agonists: additive bronchodilation effect. - Corticosteroids: may enhance anti‑inflammatory response.